Nuvalent Inc vs SoundHound AI Inc — how do they compare? Nuvalent Inc trades at $123.96 (market cap $9.81B), while SoundHound AI Inc trades at $6.56 (market cap $2.75B). The key difference: Nuvalent Inc is far larger — about 3.6× SoundHound AI Inc's market cap, and Nuvalent Inc is trading nearer its 52-week high, SoundHound AI Inc nearer its low. Which is the better fit depends on your goals.
| NUVL | SOUN | |
|---|---|---|
Market Cap | $9.81B | $2.75B |
Sector | Technology | Technology |
52-Week High | $123.96 | $21.40 |
52-Week Low | $72.16 | $5.90 |
Enterprise Value | $8.52B | $2.54B |
Signals from Pluang's Aura AI — not financial advice
Nuvalent (NUVL) trades at $123.96, showing no change recently, with technical indicators presenting a mixed signal—moving averages are bullish while oscillators are bearish. The company reported a net loss of $425.38 million for 2025, with negative profitability metrics like ROE of -41.19%. Recent news highlights GSK's proposed acquisition of Nuvalent for $124 per share, totaling $10.6 billion, which is under investigation by multiple law firms for fairness concerns.
The investment outlook is heavily influenced by the pending acquisition, offering a near-term exit at $124 per share. However, risks include ongoing financial losses, negative cash flow from operations, and legal scrutiny over the deal's adequacy. Analyst sentiment is mixed with 42% buy ratings, but the acquisition provides a clear valuation anchor amid fundamental challenges.
SoundHound AI (SOUN) trades at $6.31, up 0.64% today, but remains down 37% year-to-date. The stock shows a bearish technical trend with neutral oscillators. Fundamentally, revenue grew to $168.92 million in 2025, but net losses widened to -$14.01 million. Recent news highlights its leadership in conversational AI, yet concerns over cash burn persist. Analyst consensus is bullish with a $13.00 price target, indicating significant potential upside from current levels.
Outlook: High growth potential in voice AI markets contrasts with persistent losses and negative cash flow. Investment opportunity lies in market expansion and acquisitions, but risks include execution challenges and sustained cash burn. Investors should weigh the bullish analyst targets against the company's current unprofitability and high valuation multiples.
Trailing returns across standard periods
Latest headlines on both assets
Nuvalent, Inc. is a clinical-stage oncology company focused on creating precisely targeted therapies for patients with cancers driven by specific gene mutations. The company leverages a deep understanding of structural biology and medicinal chemistry to design novel small-molecule kinase inhibitors to overcome resistance mechanisms in advanced solid tumors. Nuvalent is committed to developing its pipeline of candidates to address high unmet needs in the treatment of various cancers.
Read more on NUVL →SoundHound AI, Inc. is a leading innovator in voice artificial intelligence, specializing in conversational intelligence technology. The company develops a platform that allows businesses to add custom voice assistants and natural language processing capabilities to their products and services, ranging from in-car systems and smart speakers to mobile apps and IoT devices. SoundHound's core technology, including its proprietary speech recognition and natural language understanding models, aims to enable fast, accurate, and deeply integrated voice AI experiences across various industries.
Read more on SOUN →